Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...

The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or pill, market to be a new meaningful target for newer players, according to investors. Lilly is the ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

Pfizer (PFE) stock was up on Monday despite the pharmaceutical company ending the clinical trial of its once-daily GLP-1 weight loss pill, ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Capping more than two years of stock-gyrating drama, Pfizer said it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another ...

Pfizer has discontinued its experimental weight-loss pill danuglipron after a trial patient experienced potential ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Pfizer shares moved lower in premarket trading Monday after the drugmaker said it is scrapping its experimental weight-loss pill danuglipron, keeping the company on the sidelines of the booming ...